Literature DB >> 11160717

Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes.

H J Netter1, T B Macnaughton, W P Woo, R Tindle, E J Gowans.   

Abstract

The small envelope protein of hepatitis B virus (HBsAg-S) can self-assemble into highly organized virus like particles (VLPs) and induce an effective immune response. In this study, a restriction enzyme site was engineered into the cDNA of HBsAg-S at a position corresponding to the exposed site within the hydrophilic a determinant region (amino acid [aa] 127-128) to create a novel HBsAg vaccine vector allowing surface orientation of the inserted sequence. We inserted sequences of various lengths from hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) E2 protein containing immunodominant epitopes and demonstrated secretion of the recombinant HBsAg VLPs from transfected mammalian cells. A number of different recombinant proteins were synthesized, and HBsAg VLPs containing inserts up to 36 aa were secreted with an efficiency similar to that of wild-type HBsAg. The HVR1 region exposed on the particles retained an antigenic structure similar to that recognized immunologically during natural infection. VLPs containing epitopes from either HCV-1a or -1b strains were produced that induced strain-specific antibody responses in immunized mice. Injection of a combination of these VLPs induced antibodies against both HVR1 epitopes that resulted in higher titers than were achieved by vaccination with the individual VLPs, suggesting a synergistic effect. This may lead to the development of recombinant particles which are able to induce a broad anti-HCV immune response against the HCV quasispecies or other quasispecies-like infectious agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160717      PMCID: PMC114797          DOI: 10.1128/JVI.75.5.2130-2141.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody.

Authors:  S Taniguchi; H Okamoto; M Sakamoto; M Kojima; F Tsuda; T Tanaka; E Munekata; E E Muchmore; D A Peterson; S Mishiro
Journal:  Virology       Date:  1993-07       Impact factor: 3.616

2.  Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

Authors:  R Schirmbeck; K Melber; T Mertens; J Reimann
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

3.  Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo.

Authors:  R Schirmbeck; K Melber; A Kuhröber; Z A Janowicz; J Reimann
Journal:  J Immunol       Date:  1994-02-01       Impact factor: 5.422

4.  Vaccination of chimpanzees against infection by the hepatitis C virus.

Authors:  Q L Choo; G Kuo; R Ralston; A Weiner; D Chien; G Van Nest; J Han; K Berger; K Thudium; C Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

5.  Expression of hepatitis delta virus RNA deletions: cis and trans requirements for self-cleavage, ligation, and RNA packaging.

Authors:  D W Lazinski; J M Taylor
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

6.  Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization.

Authors:  P Farci; H J Alter; D C Wong; R H Miller; S Govindarajan; R Engle; M Shapiro; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

7.  Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection.

Authors:  N Kato; Y Ootsuyama; H Sekiya; S Ohkoshi; T Nakazawa; M Hijikata; K Shimotohno
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  A topological model for hepatitis B surface antigen.

Authors:  H J Stirk; J M Thornton; C R Howard
Journal:  Intervirology       Date:  1992       Impact factor: 1.763

9.  Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses.

Authors:  Y K Shimizu; M Hijikata; A Iwamoto; H J Alter; R H Purcell; H Yoshikura
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment.

Authors:  A P Huovila; A M Eder; S D Fuller
Journal:  J Cell Biol       Date:  1992-09       Impact factor: 10.539

View more
  22 in total

1.  Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.

Authors:  Andrés Báez-Astúa; Elsa Herráez-Hernández; Natalio Garbi; Hilda A Pasolli; Victoria Juárez; Harald Zur Hausen; Angel Cid-Arregui
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1.

Authors:  C Li; D Candotti; J P Allain
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model.

Authors:  Michael Kotiw; Megan Johnson; Manisha Pandey; Scott Fry; Stuart L Hazell; Hans J Netter; Michael F Good; Colleen Olive
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

4.  Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence.

Authors:  Ira Berkower; Angelo Spadaccini; Hong Chen; Danah Al-Awadi; Jacqueline Muller; Yamei Gao; Dino Feigelstock; Konstantin Virnik; Yisheng Ni
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

5.  Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.

Authors:  Wai-Ping Woo; Tracy Doan; Karen A Herd; Hans-Jürgen Netter; Robert W Tindle
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Large hepatitis delta antigen is not a suppressor of hepatitis delta virus RNA synthesis once RNA replication is established.

Authors:  Thomas B Macnaughton; Michael M C Lai
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.

Authors:  Arvind Varsani; Anna-Lise Williamson; Debbie de Villiers; Inga Becker; Neil D Christensen; Edward P Rybicki
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.

Authors:  Michiko Hyakumura; Renae Walsh; Morten Thaysen-Andersen; Natalie J Kingston; Mylinh La; Louis Lu; George Lovrecz; Nicolle H Packer; Stephen Locarnini; Hans J Netter
Journal:  J Virol       Date:  2015-09-02       Impact factor: 5.103

Review 9.  Prospects for prophylactic hepatitis C vaccines based on virus-like particles.

Authors:  Elodie Beaumont; Philippe Roingeard
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

10.  Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus.

Authors:  Jin-Won Youn; Yu-Wen Hu; Nancy Tricoche; Wolfram Pfahler; Mohamed Tarek Shata; Marlene Dreux; François-Loic Cosset; Antonella Folgori; Dong-Hun Lee; Betsy Brotman; Alfred M Prince
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.